[(S)-1-((S)-1-{(1S,2R,4S)-1-Benzyl-4-[(S)-2-((S)-2-benzyloxycarbonylamino-propionylamino)-3-methyl-butyrylamino]-2-hydroxy-3-oxo-5-phenyl-pentylcarbamoyl}-2-methyl-propylcarbamoyl)-ethyl]-carbamic acid benzyl ester

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: [(S)-1-((S)-1-{(1S,2R,4S)-1-Benzyl-4-[(S)-2-((S)-2-benzyloxycarbonylamino-propionylamino)-3-methyl-butyrylamino]-2-hydroxy-3-oxo-5-phenyl-pentylcarbamoyl}-2-methyl-propylcarbamoyl)-ethyl]-carbamic acid benzyl ester
• 英文别名: benzyl N-[(1S)-2-[[(1S)-1-[[(1S,2R,4S)-1-benzyl-4-[[(2S)-2-[[(2S)-2-(benzyloxycarbonylamino)propanoyl]amino]-3-methyl-butanoyl]amino]-2-hydroxy-3-oxo-5-phenyl-pentyl]carbamoyl]-2-methyl-propyl]amino]-1-methyl-2-oxo-ethyl]carbamate；benzyl N-[(2S)-1-[[(2S)-1-[[(2S,3R,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[(2S)-2-(phenylmethoxycarbonylamino)propanoyl]amino]butanoyl]amino]-4-oxo-1,6-diphenylhexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]carbamate
• 化学式: C₅₀H₆₂N₆O₁₀
• 分子量: 907.076
• InChiKey: OUZUQRKARZFZJH-ZUIKDLEHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  66
• 可旋转键数：
  25
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  230
• 氢给体数：
  7
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  TL3 在 二甲基二环氧乙烷 作用下， 以 氘代氯仿 、 丙酮 为溶剂， 以63%的产率得到[(S)-1-((S)-1-{(1S,2R,4S)-1-Benzyl-4-[(S)-2-((S)-2-benzyloxycarbonylamino-propionylamino)-3-methyl-butyrylamino]-2-hydroxy-3-oxo-5-phenyl-pentylcarbamoyl}-2-methyl-propylcarbamoyl)-ethyl]-carbamic acid benzyl ester
  参考文献：
  名称：

  Development of a New Type of Protease Inhibitors, Efficacious against FIV and HIV Variants

  摘要：

  Based on the structural analysis of FIV protease and drug-resistant HIV proteases and molecular modeling, a new type of inhibitors with a small P3 residue has been developed. These inhibitors are effective against HIV and its drug-resistant mutants, as well as SIV and FIV. Modification of existing HIV protease inhibitors by reducing the size of the P3 residue has the same effect. This finding provides a new strategy for the development of HIV protease inhibitors effective against the wild-type and drug-resistant mutants. It further supports the use of FIV protease as a useful model for drug-resistant HIV proteases, which often have a more constricted binding region for the P3 group or the combined P3 and P1 groups.

  DOI：

  10.1021/ja982893p